| Literature DB >> 23956949 |
Bodour Al-Assil1, Maysa Mahfoud, Abdul Rezzak Hamzeh.
Abstract
Horizontal gene transfer (HGT) introduces advantageous genetic elements into pathogenic bacteria using tools such as class1 integrons. This study aimed at investigating the distribution of these integrons among uropathogenic E. coli (UPEC) isolated from patients in Aleppo, Syria. It also set to uncover the frequencies of the clinically relevant DfrA1 and DfrA17,7, as well as various associations leading to reduced susceptibility. This study involved 75 Trimethoprim-resistant E. coli isolates from in- and outpatients with urinary tract infections (UTIs) from 3 major hospitals in Aleppo. Bacterial identification, resistance and extended-spectrum-β-lactamase (ESBL) production testing were performed according to Clinical Laboratory Standards Institute guidelines. Detection of integrons and DfrA genes was done using PCR and statistical significance was inferred through χ2 (Fisher's) test. Class1 integrons were detected in 54.6% of isolates while DfrA1 and DfrA17,7 were found in 16% and 70.6% of tested samples respectively. Furthermore, only DfrA17,7 were strongly associated with class1 integrons, as were reduced susceptibility to the majority of individual antibiotics, multidrug resistance and ESBL production. This study demonstrated the high prevalence of class1 integrons among UPEC strains in Aleppo, Syria, as well as their significant associations with MDR. This data give information for local healthcare provision using antibiotic chemotherapy.Entities:
Keywords: DfrA1; DfrA17,7; antibiotic resistance; urinary tract infections
Year: 2013 PMID: 23956949 PMCID: PMC3742597 DOI: 10.4161/mge.25204
Source DB: PubMed Journal: Mob Genet Elements ISSN: 2159-2543
Table 1. Antibiotic susceptibility phenotypes of tested isolates
| Percent susceptible | |
|---|---|
| Amoxicillin-Clavulanic acid (code CT0223B) | 42.66 |
| Cefepime (code CT0771B) | 58.66 |
| Ceftazidime (code CT0412B) | 56 |
| Cefotaxime (code CT0166B) | 49.33 |
| Nitrofurantoin (code CT0036B) | 96 |
| Piperacillin-Tazobactam (code CT0725B) | 62.66 |
| Aztreonam (code CT0264B) | 61.33 |
| Amikacin (code CT0107B) | 90.66 |
| Imipenem (code CT0455B) | 100 |
| Cefoxitin (code CT0119B) | 81.33 |
| Tigecycline (code CT1841B) | 100 |
| Ceftriaxone (code CT0417B) | 48 |
| Trimethoprim-Sulfamethoxazole (code CT0052B) | 20 |
| Ampicillin-Sulbactam (code CT0520B) | 12 |
| Tobramycin (code CT0056B) | 50.66 |
| Ciprofloxacin (code CT0425B) | 66.66 |
| Nalidixic acid (code CT0031B) | 44 |
| Tetracycline (code CT0054B) | 44 |
| Chloramphenicol (code CT0013B) | 77.33 |
Table 2. Association between susceptibility to individual antibiotics, ESBL and MDR status and the presence of class 1 integrons in uropathogenic E coli isolates from Aleppo, Syria
| Antibiotic resistance-related phentype | Number of isolates | Association with integrons (p value)a | ||
|---|---|---|---|---|
| | | | ||
| Amoxicillin-Clavulanic acid | Susceptible | 11 | 21 | |
| Non susceptible | 30 | 13 | ||
| Cefepime | Susceptible | 14 | 30 | |
| Non susceptible | 27 | 4 | ||
| Ceftazidime | Susceptible | 12 | 30 | |
| Non susceptible | 29 | 4 | ||
| Cefotaxime | Susceptible | 9 | 28 | |
| Non susceptible | 32 | 6 | ||
| Nitrofurantoin | Susceptible | 41 | 31 | |
| Non susceptible | 0 | 3 | ||
| Piperacillin-Tazobactam | Susceptible | 21 | 26 | |
| Non susceptible | 20 | 8 | ||
| Aztreonam | Susceptible | 17 | 29 | |
| Non susceptible | 24 | 5 | ||
| Amikacin | Susceptible | 34 | 34 | |
| Non susceptible | 7 | 0 | ||
| Cefoxitin | Susceptible | 28 | 33 | |
| Non susceptible | 13 | 1 | ||
| Ceftriaxone | Susceptible | 9 | 27 | |
| Non susceptible | 32 | 7 | ||
| Trimethoprim-Sulfamethoxazole | Susceptible | 1 | 14 | |
| Non susceptible | 40 | 20 | ||
| Ampicillin-Sulbactam | Susceptible | 2 | 7 | 0.0701 |
| Non susceptible | 39 | 27 | ||
| Tobramycin | Susceptible | 13 | 25 | |
| Non susceptible | 28 | 9 | ||
| Ciprofloxacin | Susceptible | 17 | 33 | |
| Non susceptible | 24 | 1 | ||
| Nalidixic acid | Susceptible | 7 | 26 | |
| Non susceptible | 34 | 8 | ||
| Tetracycline | Susceptible | 14 | 19 | 0.0669 |
| Non susceptible | 27 | 15 | ||
| Chloramphenicol | Susceptible | 28 | 30 | 0.0535 |
| Non susceptible | 13 | 4 | ||
| Present | 5 | 7 | 0.3594 | |
| Absent | 36 | 27 | ||
| Present | 39 | 14 | ||
| Absent | 2 | 20 | ||
| ESBL status | Producers | 34 | 12 | |
| Non-producers | 7 | 22 | ||
| Multidrug resistance status | MDR | 41 | 12 | |
| Non-MDR | 0 | 22 | ||
a p values indicating significance are in bold.
Table 3. Association between susceptibility to individual antibiotics and the presence of dfrA17,17 in 75 uropathogenic E coli isolates from Aleppo, Syria
| Antibiotic | Number of isolates | Association with genes (p value)a | ||
|---|---|---|---|---|
| | | | ||
| Amoxicillin-Clavulanic acid | Susceptible | 19 | 13 | 0.077 |
| Non susceptible | 34 | 9 | ||
| Cefepime | Susceptible | 23 | 21 | |
| Non susceptible | 30 | 1 | ||
| Ceftazidime | Susceptible | 23 | 19 | |
| Non susceptible | 30 | 3 | ||
| Cefotaxime | Susceptible | 18 | 19 | |
| Non susceptible | 35 | 3 | ||
| Nitrofurantoin | Susceptible | 52 | 20 | 0.2041 |
| Non susceptible | 1 | 2 | ||
| Piperacillin-Tazobactam | Susceptible | 30 | 17 | 0.1189 |
| Non susceptible | 23 | 5 | ||
| Aztreonam | Susceptible | 28 | 18 | 0.0213 |
| Non susceptible | 25 | 4 | ||
| Amikacin | Susceptible | 46 | 22 | 0.0980 |
| Non susceptible | 7 | 0 | ||
| Cefoxitin | Susceptible | 41 | 20 | 0.2101 |
| Non susceptible | 12 | 2 | ||
| Ceftriaxone | Susceptible | 18 | 18 | |
| Non susceptible | 35 | 4 | ||
| Trimethoprim-Sulfamethoxazole | Susceptible | 3 | 12 | |
| Non susceptible | 50 | 10 | ||
| Ampicillin-Sulbactam | Susceptible | 5 | 4 | 0.4350 |
| Non susceptible | 48 | 18 | ||
| Tobramycin | Susceptible | 34 | 4 | |
| Non susceptible | 19 | 18 | ||
| Ciprofloxacin | Susceptible | 29 | 21 | |
| Non susceptible | 24 | 1 | ||
| Nalidixic acid | Susceptible | 14 | 19 | |
| Non susceptible | 39 | 2 | ||
| Tetracycline | Susceptible | 23 | 10 | 1.0000 |
| Non susceptible | 30 | 12 | ||
| Chloramphenicol | Susceptible | 37 | 21 | 0.0161 |
| Non susceptible | 16 | 1 | ||
a p values indicating significance are in bold.
Table 4. Sequences of primers used for detecting antibiotic resistance determinants in this study
| Target | Primer name | Primer sequence |
|---|---|---|
| dfr1-forward | 5'-TGGTAGCTATATCGAAGAATGGAG-3' | |
| dfr1-reverse | 5'-TATGTTAGAGGCGAAGTCTTGGGTA-3' | |
| dfr7,17-forward | 5'- ACATTTGACTCTATGGGTGTTCTTC-3' | |
| dfr7,17-reverse | 5'- AAAACTGTTCAAAAACCAAATTGAA-3' | |
| class 1 cassette regions | Hep58 (forward) | 5'- TCATGGCTTGTTATGACTGT-3' |
| Hep59 (reverse) | 5'- GTAGGGCTTATGCACGC-3' |